FDA extends review of Merck & Co's Gardasil
This article was originally published in Scrip
Executive Summary
The US FDA has extended a review of Merck & Co's sBLA to market its human papillomavirus (HPV)/cervical cancer vaccine Gardasil for use in women aged 27-45. Merck had been expecting a decision by next week, but now says it expects to hear from the agency by the end of the year.